|
Feb 19
|
Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4
|
|
Feb 19
|
Charles River: Q4 Earnings Snapshot
|
|
Feb 19
|
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance
|
|
Feb 18
|
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
|
|
Feb 17
|
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
|
|
Feb 14
|
Is Now the Right Time to Hold on to Charles River Stock?
|
|
Feb 13
|
Conduit Pharmaceuticals, Charles River Laboratories Partner to Evaluate Potential Lupus Treatment
|
|
Feb 12
|
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Feb 11
|
Charles River Laboratories International, Inc. (CRL) Expands AI-Powered Digital Pathology Collaboration with Deciphex
|
|
Feb 11
|
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
|
|
Jan 2
|
Should You Retain Charles River Stock in Your Portfolio Now?
|
|
Dec 5
|
Charles River Introduces Global Biotech Incubator Program
|
|
Nov 28
|
At US$200, Is It Time To Put Charles River Laboratories International, Inc. (NYSE:CRL) On Your Watch List?
|
|
Oct 18
|
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
|
|
Oct 17
|
Charles River Launches New Retrogenix® Non-Human Protein Library
|
|
Oct 16
|
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
|
|
Oct 10
|
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
|
|
Oct 3
|
Charles River Provides Translational Expertise at Neuroscience 2024
|
|
Oct 2
|
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
|
|
Sep 23
|
Charles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
|